Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Le

Showing results (21-30 of 287) with videos related to

Pageof 29
Sort By:
Clinical Trials (London, England)|February 18, 2020
Designing clinical trials with (restricted) mean survival time endpoint: Practical considerationsAnne Eaton, Terry Therneau, Jennifer Le-Rademacher
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 13, 2026
Optimizing prostate cancer stereotactic body radiotherapy: margins, dose, or target volume-de-intensification?Jennifer Le Guevelou, Paul Sargos, Thomas Zilli
International Journal of Radiation Oncology, Biology, Physics|April 15, 2022
Intraprostatic Urethra: The New Kid on the Block for Prostate Cancer Radiation Therapy?Thomas Zilli, Vérane Achard, Jennifer Le Guevelou
The French Journal of Urology|April 24, 2026
Comment on: Shams El-Din El-Behiri et al., Hypofractionated Versus Conventional IMRT in Unfavorable Intermediate- and High-Risk Prostate Cancer: A Phase II Comparative Study of PSA Kinetics, Dosimetric and Toxicity Outcomes, The French Journal of Urology, 2026Jennifer Le Guevelou, Gaelle Fiard, Michael Baboudjian
Contemporary Clinical Trials|January 20, 2022
Symbolic two-step method compared with single-step methods to model the center-mean outcome in cluster randomized trialsDavid Zahrieh, Blaize W Kandler, Jennifer Le-Rademacher
The Annals of Pharmacotherapy|October 30, 2014
Acetaminophen for patent ductus arteriosusJennifer Le, Mark A Gales, Barry J Gales
DNA Repair|April 19, 2023
Saccharomyces cerevisiae apurinic/apyrimidinic endonuclease 1 repairs abasic site-mediated DNA-peptide/protein cross-linksCameron Bryan, Jennifer Le, Xiaoying Wei, et al.
Clinical Trials (London, England)|January 20, 2024
The symbolic two-step method applied to cancer care delivery research: Safeguarding against designing an underpowered cluster randomized trial with a continuous outcome by accounting for the imprecision in the within- and between-center variationDavid Zahrieh, Blaize W Kandler, Jennifer Le-Rademacher
Chemical Research in Toxicology|May 10, 2022
Human TREX1 Repairs 3'-End DNA Lesions <i>in Vitro</i>Kun Yang, Xiaoying Wei, Jennifer Le, et al.
Computer Methods and Programs in Biomedicine|July 8, 2014
Weighted comparison of two cumulative incidence functions with R-CIFsmry packageJianing Li, Jennifer Le-Rademacher, Mei-Jie Zhang
Pageof 29

Showing results (21-30 of 287) with videos related to

Sort By:
Pageof 29
Clinical Trials (London, England)|February 18, 2020
Designing clinical trials with (restricted) mean survival time endpoint: Practical considerationsAnne Eaton, Terry Therneau, Jennifer Le-Rademacher
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 13, 2026
Optimizing prostate cancer stereotactic body radiotherapy: margins, dose, or target volume-de-intensification?Jennifer Le Guevelou, Paul Sargos, Thomas Zilli
International Journal of Radiation Oncology, Biology, Physics|April 15, 2022
Intraprostatic Urethra: The New Kid on the Block for Prostate Cancer Radiation Therapy?Thomas Zilli, Vérane Achard, Jennifer Le Guevelou
The French Journal of Urology|April 24, 2026
Comment on: Shams El-Din El-Behiri et al., Hypofractionated Versus Conventional IMRT in Unfavorable Intermediate- and High-Risk Prostate Cancer: A Phase II Comparative Study of PSA Kinetics, Dosimetric and Toxicity Outcomes, The French Journal of Urology, 2026Jennifer Le Guevelou, Gaelle Fiard, Michael Baboudjian
Contemporary Clinical Trials|January 20, 2022
Symbolic two-step method compared with single-step methods to model the center-mean outcome in cluster randomized trialsDavid Zahrieh, Blaize W Kandler, Jennifer Le-Rademacher
The Annals of Pharmacotherapy|October 30, 2014
Acetaminophen for patent ductus arteriosusJennifer Le, Mark A Gales, Barry J Gales
DNA Repair|April 19, 2023
Saccharomyces cerevisiae apurinic/apyrimidinic endonuclease 1 repairs abasic site-mediated DNA-peptide/protein cross-linksCameron Bryan, Jennifer Le, Xiaoying Wei, et al.
Clinical Trials (London, England)|January 20, 2024
The symbolic two-step method applied to cancer care delivery research: Safeguarding against designing an underpowered cluster randomized trial with a continuous outcome by accounting for the imprecision in the within- and between-center variationDavid Zahrieh, Blaize W Kandler, Jennifer Le-Rademacher
Chemical Research in Toxicology|May 10, 2022
Human TREX1 Repairs 3'-End DNA Lesions <i>in Vitro</i>Kun Yang, Xiaoying Wei, Jennifer Le, et al.
Computer Methods and Programs in Biomedicine|July 8, 2014
Weighted comparison of two cumulative incidence functions with R-CIFsmry packageJianing Li, Jennifer Le-Rademacher, Mei-Jie Zhang
Pageof 29